These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 8741235)

  • 1. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Buckley MM; Brogden RN; Barradell LB; Goa KL
    Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
    Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
    Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.
    Benfield P; Chrisp P
    Pharmacoeconomics; 1992 Jun; 1(6):443-59. PubMed ID: 10147024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of carbapenems in the treatment of nosocomial infection].
    Martínez Lacasa J; Garau J
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():78-85. PubMed ID: 9410075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F; Wu G; Zheng B
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem: laboratory and clinical data.
    Drusano G
    Clin Microbiol Infect; 1997 Feb; 3 Suppl 4():S51-S59. PubMed ID: 11869241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates].
    Azagami S; Kusumoto Y; Oikawa T; Osano M; Shiro H; Shirai Y; Nakamura M
    Jpn J Antibiot; 1988 Nov; 41(11):1704-14. PubMed ID: 3210302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing role of carbapenems in the treatment of lower respiratory tract infections.
    Lode H; Hamacher J; Eller J; Schaberg T
    Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
    Hashira S; Tajima T; Fujii R
    Jpn J Antibiot; 1989 May; 42(5):1077-86. PubMed ID: 2746857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.